Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Bronchogenic 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × belagenpumatucel L × Clear all
NCT00676507 2015-05-08

STOP

NovaRx Corporation

Phase 3 Completed
532 enrolled
Thoracic

Lung Neoplasms

NCT01058785 2010-07-29

Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer

NovaRx Corporation

Phase 2 Completed
75 enrolled
Thoracic

Carcinoma, Bronchogenic, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡